Scedosporium infection in immunocompromised patients: Successful use of liposomal amphotericin B and itraconazole

2001 ◽  
Vol 37 (2) ◽  
pp. 122-125 ◽  
Author(s):  
D. Barbaric ◽  
P.J. Shaw
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients

scholarly journals Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis

2013 ◽  
Vol 57 (7) ◽  
pp. 3340-3347 ◽  
Author(s):  
Guanpingsheng Luo ◽  
Teclegiorgis Gebremariam ◽  
Hongkyu Lee ◽  
Samuel W. French ◽  
Nathan P. Wiederhold ◽  
...  
Keyword(s):  
Fungal Infection ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Intratracheal Instillation ◽  
Cortisone Acetate ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients ◽  
Content Type ◽  
Pulmonary Mucormycosis ◽  
Life Threatening

ABSTRACTMucormycosis is a life-threatening fungal infection almost uniformly affecting diabetics in ketoacidosis or other forms of acidosis and/or immunocompromised patients. Inhalation ofMucoralesspores provides the most common natural route of entry into the host. In this study, we developed an intratracheal instillation model of pulmonary mucormycosis that hematogenously disseminates into other organs using diabetic ketoacidotic (DKA) or cyclophosphamide-cortisone acetate-treated mice. Various degrees of lethality were achieved for the DKA or cyclophosphamide-cortisone acetate-treated mice when infected with different clinical isolates ofMucorales. In both DKA and cyclophosphamide-cortisone acetate models, liposomal amphotericin B (LAmB) or posaconazole (POS) treatments were effective in improving survival, reducing lungs and brain fungal burdens, and histologically resolving the infection compared with placebo. These models can be used to study mechanisms of infection, develop immunotherapeutic strategies, and evaluate drug efficacies against life-threateningMucoralesinfections.

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients

2010 ◽  
Vol 12 (5) ◽  
pp. 428-431 ◽  
Author(s):  
E. Vigna ◽  
A. De Vivo ◽  
M. Gentile ◽  
R. Morelli ◽  
E. Lucia ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients

Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients

2013 ◽  
Vol 49 (6) ◽  
pp. 574-580 ◽  
Author(s):  
Harutai Kamalaporn ◽  
Kitty Leung ◽  
Mark Nagel ◽  
Saranya Kittanakom ◽  
Battista Calvieri ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Invasive Pulmonary Aspergillosis ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients ◽  
Pulmonary Aspergillosis

Methods for particle size reduction of liposomal amphotericin B

2018 ◽  
Vol 60 (1) ◽  
pp. 42-45
Author(s):  
Tuan Quang Nguyen ◽  
Van Lam Nguyen ◽  
Thai Son Nguyen ◽  
Thi Minh Hue Pham ◽  
◽  
...  
Keyword(s):  
Particle Size ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Size Reduction ◽  
Liposomal Amphotericin B ◽  
Particle Size Reduction
Sign in / Sign up

Export Citation Format

Share Document